---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-112945"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:10:32.200101+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech's majority-owned Cyprium gets NDA resubmission for CUTX-101 to FDA

## Summary
- Sentynl resubmitted NDA for CUTX-101 to FDA on Nov 14, 2025.
- Prior Complete Response Letter on Oct 1, 2025.
- Cyprium retains ownership of any Priority Review Voucher upon approval.
- Cyprium eligible for up to $129M in development and sales milestones plus royalties.

## SEC filing metadata
- accession: 0001104659-25-112945
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465925112945/0001104659-25-112945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465925112945/tm2531443d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-112945
- JSON: https://secwatch.observer/filing/0001104659-25-112945.json
- Plain text: https://secwatch.observer/filing/0001104659-25-112945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.